Skip to content
Review

Effects of GLP-1–Related Therapies on Lean Mass and Body Composition: A Narrative Review

Oct 2026 · Journal of Fitness, Wellness, and Human Performance · 0 citations · 54 references

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (GLP-1RAs) and incretin-based multiagonist therapies have become among the most widely prescribed medications for obesity and type 2 diabetes mellitus (T2DM) management, producing clinically meaningful reductions in body weight and fat mass (FM). Concerns have emerged regarding concomitant lean mass (LM) reduction during pharmacologically induced weight loss, particularly as higher-efficacy agents such as tirzepatide (a dual glucose-dependent insulinotropic polypeptide and GLP-1RA) and retatrutide (an investigational triple agonist not approved for clinical use) produce increasingly greater total weight losses. This narrative review synthesizes randomized controlled trial (RCT) evidence on the effects of incretin-based and multiagonist therapies on LM and body composition, with emphasis on nutritional strategies for LM preservation and the body composition implications of postcessation weight regain. Eight RCTs (7 producing net weight loss) across adult and adolescent populations with obesity, T2DM, type 1 diabetes mellitus, and hypothalamic obesity (HO) were identified as the primary evidence base. LM reductions represented approximately 25% to 40% of total weight lost, a range consistent with caloric restriction and bariatric surgery at comparable degrees of weight loss; and no trial provided evidence of selective or disproportionate LM loss independent of overall weight reduction, though none was powered to detect such an effect. Authors of a 2025 network meta-analysis of 22 RCTs, with searches conducted through November 2024, corroborated these findings reporting that LM comprised approximately 25% of total weight lost, with relative LM percentage unaffected. HO was an exception, with LM preserved absent an energy deficit. Weight regain following therapy discontinuation may preferentially restore FM, worsening body composition relative to baseline. LM preservation should emphasize resistance exercise, adequate protein intake, and sustainable lifestyle support, although direct evidence for these strategies in incretin-treated populations remains limited.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.